Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

(2012) Jin-Hua Sun et al.   HEPATOLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

(2011) A. Lok et al.   JOURNAL OF HEPATOLOGY

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A perspective on modelling hepatitis C virus infection

(2010) J. Guedj et al.   JOURNAL OF VIRAL HEPATITIS

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

(2009) J. M. Cuevas et al.   JOURNAL OF VIROLOGY